The influence of calcium channel blockers on Ca−P−Mg homeostasis and bone mass in patients with coronary heart disease and hypertension

1996 ◽  
Vol 6 (S1) ◽  
pp. 184-184 ◽  
Author(s):  
B. Kapitan-Malinowska ◽  
M. Tałalaj ◽  
E. Marcinowska-Suchowierska ◽  
J. Borowicz ◽  
H. Puchalska-Krotki
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Bone Mass ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Channel Blockers

scholarly journals Role of Calcium Channel Blockers in Myocardial Preconditioning

2017 ◽  
Vol 18 (4) ◽  
pp. 281-287 ◽  
Author(s):  
Nina Simonovic ◽  
Jovana Jeremic
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Calcium Channel ◽  
Reperfusion Injury ◽  
Calcium Channel Blockers ◽  
Channel Blockers ◽  
Ischaemia Reperfusion Injury ◽  
Ischaemia Reperfusion ◽  
Myocardial Preconditioning

AbstractCoronary heart disease is the leading cause of mortality and morbidity worldwide. The effects of coronary heart disease are usually attributable to the detrimental effects of acute myocardial ischaemia-reperfusion injury. Newer strategies such as ischaemic or pharmacological preconditioning have been shown to condition the myocardium to ischaemia-reperfusion injury and thus reduce the final infarct size. This review investigates the role of calcium channel blockers in myocardial preconditioning. Additionally, special attention is given to nicorandil whose mechanism of action may be associated with the cardioprotective effects of preconditioning. There are still many uncertainties in understanding the role of these agents in preconditioning, but future research in this direction will certainly help reduce coronary heart disease.

Calcium Channel Blockers

1992 ◽  
Vol 3 (2) ◽  
pp. 437-446
Author(s):  
Pamela White
Keyword(s):  
Heart Failure ◽  
Heart Disease ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Cardiac Disease ◽  
The Other ◽  
Cardiac Conduction ◽  
Channel Blockers ◽  
Clinical Effects ◽  
Conduction Disturbances

Calcium channel blockers are widely used in the treatment of ischemic heart disease, hypertension, and supraventricular tachycardia. The prototype agents, verapamil, nifedipine, and diltiazem, represent three classes of calcium channel blockers, each of which has different pharmacologic effects. Nifedipine and the other dihydropyridines primarily are vasodilators and have no clinical effects on cardiac conduction or contractility. Diltiazem and verapamil also are vasodilators, but they possess, to varying degrees, negative inotropic, chronotropic, and dromotropic effects. Side effects of these drugs are relatively rare and usually not serious, with the exception of potential conduction disturbances and heart failure in patients with underlying cardiac disease. To assess patients taking these medications and provide the necessary teaching, the nurse needs an understanding of the pharmacologic properties, clinical indications, and potential adverse effects of the various drugs

Sign in / Sign up

Export Citation Format

Share Document